[Pathophysiological and diagnostic aspects of Guillain-Barré syndrome]

Rev Med Interne. 2022 Jul;43(7):419-428. doi: 10.1016/j.revmed.2021.12.005. Epub 2022 Jan 6.
[Article in French]

Abstract

Guillain-Barré syndrome (GBS) is the most common cause of acute neuropathy. It usually onset with a rapidly progressive ascending bilateral weakness with sensory disturbances, and patients may require intensive treatment and close monitoring as about 30% have a respiratory muscle weakness and about 10% have autonomic dysfunction. The diagnosis of GBS is based on clinical history and examination. Complementary examinations are performed to rule out a differential diagnosis and to secondarily confirm the diagnosis. GBS is usually preceded by an infectious event in ≈ 2/3 of cases. Infection leads to an immune response directed against carbohydrate antigens located on the infectious agent and the formation of anti-ganglioside antibodies. By molecular mimicry, these antibodies can target structurally similar carbohydrates found on host's nerves. Their binding results in nerve conduction failure or/and demyelination which can lead to axonal loss. Some anti-ganglioside antibodies are associated with particular variants of GBS: the Miller-Fisher syndrome, facial diplegia and paresthesias, the pharyngo-cervico-brachial variant, the paraparetic variant, and the Bickerstaff brainstem encephalitis. Their semiological differences might be explained by a distinct expression of gangliosides among nerves. The aim of this review is to present pathophysiological aspects and the diagnostic approach of GBS and its variants.

Keywords: Diagnosis; Diagnostic; Guillain-Barre syndrome; Miller-Fisher syndrome; Pathophysiology; Physiopathologie; Syndrome de Guillain-Barré; Syndrome de Miller-Fisher.

Publication types

  • Review

MeSH terms

  • Encephalitis* / complications
  • Gangliosides
  • Guillain-Barre Syndrome* / diagnosis
  • Humans
  • Miller Fisher Syndrome* / complications
  • Muscle Weakness

Substances

  • Gangliosides